The world’s largest manufacturer of contrast agents for gastrointestinal radiology has taken a 5% equity position in PointDx, an emerging medical technology company focused on the development of virtual colonoscopy software and structured reporting
The world’s largest manufacturer of contrast agents for gastrointestinal radiology has taken a 5% equity position in PointDx, an emerging medical technology company focused on the development of virtual colonoscopy software and structured reporting solutions for radiology. The deal also provides E-Z-EM with a three-year warrant to purchase an additional 120,000 shares and one seat on the PointDx board of directors. By taking an equity stake in PointDx, E-Z-EM hopes to follow and support the development of new applications in GI medicine.
